NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis


10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.

Adalimumab, etanercept and infliximab, taken with methotrexate have been recommended for use within the NHS. Adalimumab and etanercept can also be used as monotherapy when methotrexate is contra-indicated or not tolerated.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder